Amgen Inc. (NASDAQ:AMGN) Shares Purchased by Motley Fool Asset Management LLC

Motley Fool Asset Management LLC boosted its holdings in Amgen Inc. (NASDAQ:AMGN) by 3.7% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,836 shares of the medical research company’s stock after purchasing an additional 562 shares during the quarter. Motley Fool Asset Management LLC’s holdings in Amgen were worth $4,561,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. International Assets Investment Management LLC acquired a new stake in shares of Amgen in the fourth quarter valued at approximately $4,589,900,000. Assenagon Asset Management S.A. boosted its holdings in shares of Amgen by 486.6% in the fourth quarter. Assenagon Asset Management S.A. now owns 899,232 shares of the medical research company’s stock valued at $258,997,000 after acquiring an additional 745,929 shares during the period. abrdn plc boosted its holdings in shares of Amgen by 150.4% in the fourth quarter. abrdn plc now owns 1,043,609 shares of the medical research company’s stock valued at $300,580,000 after acquiring an additional 626,810 shares during the period. Royal Bank of Canada lifted its holdings in shares of Amgen by 11.4% during the third quarter. Royal Bank of Canada now owns 5,079,677 shares of the medical research company’s stock worth $1,365,213,000 after purchasing an additional 518,689 shares during the period. Finally, California Public Employees Retirement System lifted its holdings in shares of Amgen by 22.0% during the fourth quarter. California Public Employees Retirement System now owns 2,716,088 shares of the medical research company’s stock worth $782,288,000 after purchasing an additional 490,539 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have issued reports on the company. The Goldman Sachs Group raised their price target on Amgen from $313.00 to $350.00 and gave the stock a “buy” rating in a research note on Wednesday, February 7th. Truist Financial restated a “buy” rating and set a $320.00 price objective on shares of Amgen in a research report on Friday, April 12th. Oppenheimer restated an “outperform” rating and issued a $350.00 price objective on shares of Amgen in a report on Thursday, February 1st. SVB Leerink downgraded Amgen from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $324.00 to $318.00 in a research note on Wednesday, February 7th. Finally, StockNews.com downgraded Amgen from a “buy” rating to a “hold” rating in a research note on Thursday, March 28th. Ten investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $296.95.

Amgen Trading Down 1.3 %

NASDAQ AMGN traded down $3.63 during trading on Thursday, reaching $269.38. 1,792,738 shares of the stock traded hands, compared to its average volume of 2,827,451. The firm has a market cap of $144.49 billion, a price-to-earnings ratio of 21.57, a price-to-earnings-growth ratio of 2.55 and a beta of 0.58. The stock’s 50-day moving average price is $275.38 and its 200 day moving average price is $281.46. Amgen Inc. has a fifty-two week low of $211.71 and a fifty-two week high of $329.72. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 10.14.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.66 by $0.05. The business had revenue of $8.20 billion during the quarter, compared to analyst estimates of $8.13 billion. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The firm’s quarterly revenue was up 19.8% on a year-over-year basis. During the same quarter last year, the business earned $4.09 EPS. Analysts predict that Amgen Inc. will post 19.42 EPS for the current year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be issued a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a yield of 3.34%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio is 72.06%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.